Dec. 2 at 1:51 PM
Exciting news from the biotech world! Jupiter Neurosciences, Inc. (
$JUNS on #NASDAQ), a clinical-stage pharmaceutical company focused on addressing neuroinflammation and promoting healthy aging, has just received #FDA Clearance for its IND application to kick off a Phase 2a clinical trial of #JOTROL™ in Parkinson’s disease. https://www.youtube.com/watch?v=_-2p4LWhoOw
#Stockstobuy #stockstowatch #JUNS #TeamHighAlert @Charles